North America Asthma Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America Asthma Market Overview

Asthma continues to generate demand for preventive respiratory care, ongoing medication use, and clinical monitoring throughout North America. Treatment priorities include controlling airway inflammation, reducing exacerbations, maintaining lung function, and supporting daily activities among children and adults with the condition. The market is supported by established healthcare networks, broad availability of prescription therapies, and continued advances in respiratory medicine. Inhaled medications remain fundamental to treatment, while biologic therapies provide targeted options for eligible patients with severe asthma. The market is poised to grow at a CAGR of 5.80% during the forecast period of 2026-2035, driven by research into inflammatory mechanisms, improvements in disease assessment, and evolving treatment strategies.

North America Asthma Market Growth Analysis and Key Influencers

North America Asthma Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

North America Asthma Market Growth Drivers

Increasing Availability of Affordable Asthma Medications Supports Market Expansion

The increasing availability of affordable asthma medications is supporting market expansion by improving treatment accessibility and providing patients with cost-effective alternatives to established therapies. Greater availability of generic inhaled medications can help reduce prescription expenses and expand access to essential asthma treatments. For instance, in July 2023, Viatris Inc., in partnership with Kindeva Drug Delivery, launched Breyna, the FDA-approved generic version of Symbicort in the United States. Available in two dosage strengths, the budesonide and formoterol inhalation of aerosol is indicated for eligible patients with asthma, supporting treatment accessibility and competition in the market.

North America Asthma Market Restraints

Safety Concerns Associated with Asthma Medications May Challenge Market Value

Safety concerns associated with asthma medications may limit treatment adoption and complicate long-term disease management. Potential adverse effects, including immunosuppression, increased infection risk, reduced bone mineral density, and adrenal suppression associated with inhaled corticosteroids, require appropriate monitoring. According to the University of Colorado Anschutz Medical Campus (May 2026), research also highlighted a potential association between maternal asthma and severe retinopathy of prematurity, emphasizing the importance of effective asthma control during pregnancy. Such clinical considerations may increase treatment complexity and influence prescribing decisions.

North America Asthma Market Opportunities

Advancements in Biologic and Novel Inhaled Therapies Create New Growth Potential

Advancements in targeted biologics and innovative inhaled therapies are creating new possibilities for improving asthma management, particularly among patients with severe or uncontrolled disease. These developments offer potential for more personalized treatment approaches and better prevention of exacerbations. For instance, in May 2024, AstraZeneca presented 59 abstracts at the American Thoracic Society International Conference, including research on TEZSPIRE, AIRSUPRA, and investigational inhaled therapies targeting TSLP and JAK1 pathways. Continued clinical research and pipeline development could expand treatment options and support future market growth.

North America Asthma Market Trends

The market is witnessing several trends, including advancements in biologic therapies, smart inhaler technologies, and personalized asthma management.

Increasing Adoption of Dual-Targeted Biologics to Strengthen Market Growth

The development of targeted biologic therapies is advancing asthma management by addressing multiple inflammatory pathways and improving disease control among patients with moderate-to-severe asthma. For instance, in April 2026, Sanofi announced that its investigational bispecific therapy, lunsekimig, met the primary and key secondary endpoints in its Phase 2b AIRCULES study, demonstrating reduced asthma exacerbations and improved lung function. Such advancements are expected to expand treatment options and support the growth of the asthma market.

North America Asthma Market Share

Inhaled Route of Administration to Maintain Dominance in the Market

The market is segmented by route of administration into inhaled, oral, injectable, and other routes. Among these, the inhaled segment is expected to lead the market, supported by the widespread use of inhalers for delivering asthma medications directly into the lungs. The increasing integration of digital technologies is further improving medication adherence and administration techniques. For instance, in October 2021, BreatheSuite received FDA 510(k) clearance for its smart metered-dose inhaler device, which monitors inhaler technique and medication adherence. These developments are expected to reinforce the segment's dominance and support overall market growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

North America Asthma Market Analysis by Region

The regions included in the report are the United States and Canada. Among these, the United States is expected to lead the market, supported by its large patient population, growing healthcare infrastructure, and increasing adoption of advanced asthma treatments. Improvements in treatment approaches and the availability of combination therapies are also expected to support regional demand. For instance, in May 2025, Vanderbilt Health reported findings from the BATURA trial, demonstrating that as-needed albuterol-budesonide significantly reduced severe asthma exacerbations compared with albuterol alone. Such therapeutic advancements are expected to support market growth.

Leading Players in the North America Asthma Market

North America Asthma Market Segmentation

Key Questions Answered in the North America Asthma Market Report

• What was the North America asthma market value in 2025?
• What is the North America asthma market forecast outlook for 2026-2035?
• What are the major factors aiding the North America asthma market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major asthma market trends?
• Which disease severity is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which age group is likely to dominate the market segment?
• Which distribution channel is anticipated to lead the market segment?
• Who are the key players involved in the North America asthma market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews conducted with pulmonologists, allergists, immunologists, respiratory specialists, asthma care physicians, hospital procurement managers, pharmaceutical executives, and payer representatives across the United States and Canada. Discussions focus on treatment preferences, prescription trends, biologic adoption, patient access, reimbursement practices, and evolving clinical requirements.
• Secondary Research: Peer-reviewed publications from the Journal of Allergy and Clinical Immunology (JACI), American Journal of Respiratory and Critical Care Medicine, The Lancet Respiratory Medicine, and Chest; regulatory and clinical resources from the US Food and Drug Administration (FDA), Health Canada, ClinicalTrials.gov, National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and World Health Organization (WHO); epidemiological information from national health surveys, including the National Health and Nutrition Examination Survey (NHANES) and Canadian Community Health Survey (CCHS); and company disclosures, annual reports, product portfolios, clinical trial announcements, and investor presentations from leading asthma treatment developers.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling, with cross-validation against epidemiological indicators, treatment utilization patterns, drug pricing, sales disclosures, and expert feedback to ensure consistency and reliability of market estimates.